Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of “Buy” by Brokerages

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has earned a consensus recommendation of “Buy” from the ten analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $20.89.

Several equities research analysts have recently issued reports on YMAB shares. HC Wainwright reissued a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Wednesday, December 11th. Brookline Capital Management began coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price objective on the stock. Finally, Oppenheimer initiated coverage on Y-mAbs Therapeutics in a research note on Monday, November 18th. They set an “outperform” rating and a $23.00 target price for the company.

Y-mAbs Therapeutics Stock Down 3.4 %

Y-mAbs Therapeutics stock opened at $7.39 on Friday. Y-mAbs Therapeutics has a 52 week low of $6.92 and a 52 week high of $20.90. The firm has a market cap of $330.99 million, a price-to-earnings ratio of -13.69 and a beta of 0.69. The business’s 50-day moving average price is $10.62 and its 200 day moving average price is $12.20.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The firm had revenue of $18.46 million for the quarter, compared to analysts’ expectations of $23.38 million. During the same period last year, the firm earned ($0.18) earnings per share. Equities analysts expect that Y-mAbs Therapeutics will post -0.66 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in YMAB. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Y-mAbs Therapeutics in the third quarter valued at approximately $44,000. China Universal Asset Management Co. Ltd. grew its holdings in Y-mAbs Therapeutics by 66.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock valued at $113,000 after buying an additional 3,416 shares in the last quarter. Intech Investment Management LLC purchased a new stake in Y-mAbs Therapeutics in the 3rd quarter valued at $133,000. SG Americas Securities LLC acquired a new stake in shares of Y-mAbs Therapeutics in the 3rd quarter worth $178,000. Finally, Empire Financial Management Company LLC purchased a new position in shares of Y-mAbs Therapeutics during the 3rd quarter worth $210,000. 70.85% of the stock is owned by institutional investors and hedge funds.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.